Immunogenicity and overexpression of PCR-synthesizing gene of heavy chain from C-terminal binding domain of botulinum neurotoxin type A

Chinese Journal of Microbiology and Immunology

Volumn 26, Issue 1, 2006, Pages 27-31

  Yang, Li Min ^a   Wang, Jing Lin ^b   Hu, Ting Mao ^b  

^a INNER MONGOLIA UNIVERSITY   (China)

^b NONE

Author keywords

Affinity chromatography; Antigenicity; BoNT A; On column refolding

Indexed keywords

BOTULINUM TOXIN A; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM BOTULINUM; CODON; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE OVEREXPRESSION; HEAVY CHAIN; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PURIFICATION; WESTERN BLOTTING;

EID: 33646010628     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Arnon SA, Schecter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA, 2001, 285: 1059-1070.
2. Bavari S, Pless DD, Torres ER, et al. Identifying the principle protective antigenic determinants of type A botulinum neurotorin. Vaccine, 1998, 16: 1850-1856.
3. Wu HC, Yeh CT, Huang YL, et al. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Appl Environ Microbiol, 2001, 67: 3201-3207.
4. Clayton MA, Clayton JM, Brown DR, et al. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun, 1995, 63: 2738-2742.
5. Byrne MP, Smith TJ, Montgomery VA, et al. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun, 1998, 66: 4817-4822.
6. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon, 1998, 36: 1539-1548.
7. Wang LC, Kang L, Hu TM, et al. Abrin-a A chain expressed as soluble form in Escherichia coli from a PCR-synthesized gene is catalytically and functionally active. Biochimie, 2004, 86: 327-333.
8. Kirazov LP, Venkov LG, Kirazov EP. Comparison of the lowry and the bradford protein assays as applied for protein estimation of membrane-containing fractions. Anal Biochem, 1993, 208: 44-48.
9. Potter KJ, Zhang WH, Smith LA, et al. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Exp Purif, 2000, 19: 393-402.
10. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie, 2000, 82: 955-966.
11. Tavallaie M, Chenal A, Gillet D, et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett, 2004, 572: 299-306.
12. Saini DK, Pant N, Das TK, et al. Cloning, overexpression, purification, and matrix-assisted refolding of DevS(Rv 3132c) histidine protein kinase of Mycobacterium tuberculosis. Protein Expr Purif, 2002, 25: 203-208.